PG 22000
Alternative Names: PG 2-2000Latest Information Update: 10 Jan 2008
At a glance
- Originator Pharmagenesis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological disorders
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Haematological disorders in USA (unspecified route)
- 08 Nov 2001 Preclinical development for Haematological disorders in USA (unspecified route)